Uses of Klor-Con M20

Klor-Con M20 is an extended-release tablet containing potassium chloride, an essential electrolyte required for the proper functioning of various physiological systems. The primary purpose of this medication is to manage the balance of potassium in the body.

Treatment of Hypokalemia

The most common use of Klor-Con M20 is for the treatment of hypokalemia, a condition characterized by low levels of potassium in the bloodstream. Potassium is vital for the transmission of nerve impulses, the contraction of cardiac, skeletal, and smooth muscles, and the maintenance of normal kidney function.

Prevention of Potassium Depletion

In certain clinical scenarios, Klor-Con M20 is used to prevent the development of potassium deficiency. This is particularly relevant for individuals who are at a higher risk of losing potassium due to specific medical conditions or the use of other medications that increase potassium excretion through the urine.

Benefits of Potassium Supplementation

Maintaining adequate potassium levels through the use of Klor-Con M20 provides several physiological benefits:

• Muscle Function: It supports the regular contraction and relaxation of muscles throughout the body.
• Heart Rhythm Regulation: Proper potassium levels are necessary for maintaining a stable and regular heartbeat.
• Fluid Balance: As an electrolyte, potassium helps regulate the balance of fluids and acid-base levels within cells.
• Nerve Signaling: It facilitates the electrical signals that allow the nervous system to communicate effectively with the rest of the body.

Regulatory References

1. NIH DailyMed label for Potassium Chloride Extended-release Tablets

Eligibility Scope

Age-Related and Organ Function Eligibility

Age-related eligibility rules: Use is established for pediatric patients. For elderly patients, dose selection should be cautious, typically starting at the low end of the dosing range, due to the greater frequency of decreased renal function.

Condition-specific eligibility rules: Patients with impaired renal function are at a substantially increased risk of hyperkalemia and require particularly careful monitoring. Patients with cirrhosis must also be started at a low initial dose and monitored frequently.

Pregnancy and lactation eligibility status: The medicine should be given during pregnancy only if clearly needed. Use during lactation is generally considered acceptable and is not expected to cause harm to the nursing infant, provided the mother’s potassium level is not excessive.

Connection to the overall eligibility profile: Official regulatory documents define eligibility primarily by establishing absolute contraindications based on existing high potassium levels or specific co-medications. Use is conditional in populations with reduced potassium excretion capacity, requiring close monitoring.

The interaction profile for Klor-Con M20 (Potassium Chloride Extended-Release) focuses on substances that increase total systemic potassium load or interfere with the specialized tablet formulation.

The most critical restriction is the formal contraindication against combining Klor-Con M20 with any potassium-sparing diuretics, such as spironolactone, triamterene, or amiloride, and against using any other potassium-containing salts or supplements. These combinations are prohibited because they create a high risk of severe hyperkalemia (excessive potassium in the blood).

Additional clinically significant pharmacodynamic interactions exist with medications that affect the body’s potassium regulation. These include ACE Inhibitors (like lisinopril), Angiotensin II Receptor Blockers (ARBs), and Direct Renin Inhibitors, which can lead to elevated plasma potassium levels. The co-administration of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may also contribute to the risk of hyperkalemia, a risk which is documented to be heightened in patients with impaired renal function.

Regarding the formulation, anticholinergic drugs may decrease intestinal transit time, which can potentially affect the controlled release of the potassium chloride crystals. Furthermore, regulatory information advises avoiding the use of potassium-containing salt substitutes as they contribute an additional potassium burden, raising the potential for hyperkalemia.

Restoration of the Transmembrane Electrochemical Gradient

Klor-Con M20’s mechanism of action is electrolyte replacement, providing the essential potassium ion ( K^+) substrate. The primary biological target is the Sodium-Potassium ( Na^+/ K^+) ATPase pump , which utilizes the K^+ to actively re-establish the steep concentration differential across the cell membrane. This action sets the cell’s resting membrane potential, the electrical foundation required for cellular excitability.

Modulation of Systemic Electrophysiology

Re-establishing the correct electrochemical gradient modulates the function of Potassium Ion Channels ( K v and K ir) during the action potential cycle. This modulates electrical processes in the Cardiac Electrophysiology Pathway, facilitating efficient repolarization and electrical stability, and also modulating neuromuscular excitability.

Mechanism of Sustained Delivery

This preparation utilizes a mechanical design featuring microencapsulated KCl crystals. This formulation governs the dissolution kinetics, ensuring a slow, sustained diffusion of the ion throughout the gastrointestinal tract. This controlled delivery rate prevents high, localized concentrations of KCl in the gut lumen, which provides for continuous and sustained delivery of the ion.

How to Use Klor-Con M20 (Potassium Chloride Extended-Release Tablets)

These instructions outline the proper administration of Klor-Con M20. Klor-Con M20 is an extended-release microencapsulated tablet formulation for oral administration.

Official Administration Guidelines

Dosing and Schedule

The dosage is determined by a healthcare provider based on the patient's potassium levels. Doses are typically expressed in milliequivalents (mEq). Klor-Con M20 is a 20 mEq strength tablet.

Note on Special Use: The total daily dosage should generally not exceed 200 mEq. For patients with renal impairment or those over 65, dosing should be initiated at the low end of the dosing range.

If swallowing is difficult, the tablet may be broken in half and swallowed, or dissolved in 4 ounces of water for two minutes, stirred, and the mixture drunk immediately. The shell of the extended-release tablet is not absorbed and may be visible in the stool.

Research Evidence / Overview of Studies for Klor-Con M20

Evidence for the Treatment and Prevention of Low Blood Potassium (Hypokalemia)

Research has explored the use of the active ingredient in Klor-Con M20, potassium chloride, for which research examined outcomes related to serum potassium concentration, a vital outcome related to systemic or functional imbalance. Studies designed as short-term Randomized Controlled Trials (RCTs) were conducted in adult populations, including those who may lose potassium due to long-term diuretic use. The studies report how potassium levels evolved, describing how the serum potassium concentration, which is used as a surrogate outcome, shifted toward the target range.

However, research provides limited insight into long-term outcomes for this specific formulation. While studies monitored the short-term goal of correcting the potassium biomarker, long-term effects are not fully established regarding high-level clinical outcomes.

Studies on Muscular Symptoms and Physical Comfort

Klor-Con M20 was studied for outcomes related to physical discomfort. Research examined short-term symptom changes, particularly focusing on symptoms such as muscular cramping or weakness that are associated with low potassium levels. The available evidence is limited, as the studies conducted were often small-scale pilot trials involving very narrow and specific populations. Because the research has been conducted on small sample sizes, generalizability is uncertain, meaning there is limited information for how Klor-Con M20 might influence general muscular discomfort in the broader population.

Understanding the Extended-Release Formulation in Research

The Micro-Dispersible Technology used in Klor-Con M20 was evaluated in studies known as Bioequivalence or Pharmacokinetic (PK) studies. The research examined how the body handles the extended-release form, comparing its absorption and release characteristics against other potassium forms. Data show patterns related to the release profile of the medication, describing that the extended-release formulation was designed to provide a more gradual delivery of potassium ions over time. A key limitation of these PK studies is that the sample sizes were modest, and data for certain groups with complex health needs remain insufficient.

Key Studies & References

1. Klor-Con (potassium chloride) Extended-Release Tablets Prescribing Information and FDA Labeling
2. Potassium Chloride - StatPearls (Source for core physiological and clinical context on hypokalemia and KCL use)

Common questions about Klor-Con M20 (FAQ)

Q: What should I do if I miss a dose of Klor-Con M20?

The official guidance is to take the missed dose as soon as it is remembered. However, if it is almost time for the next scheduled dose, the recommendation is to take only that next dose. Official drug information states that extra medicine should not be taken to make up for the missed dose.

Q: Is it possible for Klor-Con M20 to cause a severe allergic reaction?

Serious allergic reactions to this medication are considered rare, according to regulatory documents. Signs of a severe reaction can include a rash, swelling of the face, tongue, or throat, or trouble breathing. If any severe symptoms are experienced, patients are advised to seek medical help right away.

Q: If my low potassium is fixed, do I need to keep taking Klor-Con M20?

The length of treatment is determined by a healthcare provider based on the patient’s individual potassium levels and overall clinical response. Official product information states that patients should not discontinue the medication unless instructed to do so by a healthcare provider.

Q: What foods should I avoid while on Klor-Con M20?

The official label specifically cautions against using potassium-containing salt substitutes. This is because they contribute additional potassium, which may increase the risk of having too much potassium in the blood (hyperkalemia). For patients with specific dietary concerns or medical conditions that affect potassium, consulting with a healthcare provider about diet is generally advised.

How to Store and Dispose of Klor-Con M20

Klor-Con M20 (potassium chloride extended-release tablets) must be stored at Controlled Room Temperature, which is officially defined as 20 C to 25 C (68 F to 77 F). Temporary excursions between 15 C to 30 C (59 F to 86 F) are permitted, but storage must remain within this regulated range to maintain product stability.

Packaging and Child Safety

To ensure quality, the medication must be stored in a tightly closed container. Like all medicines, Klor-Con M20 must be kept out of reach of children to prevent accidental ingestion.

Disposal Instructions

Official regulatory information requires that any unused or expired Klor-Con M20 tablets must be disposed of according to local regulations.